Patients and caregivers report a higher incidence of dementia with Lewy bodies.

Published Date: 12 Mar 2023

Patients and caregivers report a higher incidence of dementia with Lewy bodies.

Read Full News

Latest News

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome Matt Hoffman

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Latest News

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

News All Time

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.

12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease Louie Pasculli

Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy Marco Meglio

Seven investigational cerebral palsy therapies—from baby-tooth stem cells to cannabinoids and botulinum toxin—show mixed early results, highlighting key clinical trial milestones ahead.

GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease Marco Meglio

Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.

Recommended News For You

What Role Should Genomic Classifier Testing Play in Prostate Cancer?

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

Telemedicine Not Reaching Rural Psychiatric Patients

FDA Expands Durvalumab Label to Operable Lung Cancer

Significant worldwide disparities seen in availability and timeliness of new cancer drugs

Talquetamab Regimens Boost Survival in Multiple Myeloma

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

Recommended Articles For You

AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies 

Modern Strategies in Hematology for Specialists 

Personalized Hematology Through Patient-Specific Cellular Profiles 

Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars

2.

The Growing Role of AI in Cancer Treatment

3.

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

4.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

5.

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training

1.

Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies

2.

Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

3.

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025

4.

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

5.

Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

3.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

4.

How Multidisciplinary Teams Support Modern Cancer Care

5.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot